Table 6.

Observational studies comparing OCT and OCTA measurements between intravitreal anti-VEGF and LPC treatment modalities, in infants with TR-ROP

Authors/first author	Year	Participants	Treatment modalities being compared	Outcomes	Risk of bias assessment with ROBINS-I tool9
Chen et al. [16]	2019	47 eyes of 25 infants with type 1 ROP	IVB (0.625 mg/0.025 ml), Diode LPC	At 1 year post-treatment, IVB group had:  Lower mean IFT (P = 0.002)  Lower mean foveal VD (P = 0.020)  Higher mean FAZ (P = 0.004)  Higher mean parafoveal VD (P = 0.010) No differences between groups in:  Mean OFT (P = 0.180)  Mean subfoveal CT (P = 0.450)  Mean perifoveal VD (P = 0.460)  Mean foveal VD (P = 0.050)	Critical overall risk of bias due to selection bias
Lee et al. [20]	2018	80 eyes of 42 patients with type 1 ROP	IVB (0.625 mg/0.025 ml), Diode LPC, IVB (0.625 mg/0.025 ml) + diode LPC	The IVB monotherapy group had:  Lower mean foveal thickness (P < 0.010)  Lower mean parafoveal (P < 0.010)  Lower mean perifoveal thickness (P < 0.010) No differences between groups in:  Subfoveal CT (P = 0.210)  Macular CT (P = 0.230)	Critical overall risk of bias due to selection bias

OCT optical coherence tomography, OCTA optical coherence tomography angiography, anti-VEGF anti-vascular endothelial growth factor, LPC laser photocoagulation, TR-ROP treatment-requiring retinopathy of prematurity, ROBINS-I risk of bias in non-randomized studies of interventions, ROP retinopathy of prematurity, IVB intravitreal bevacizumab, IFT inner foveal thickness, VD vessel density, FAZ foveal avascular zone, OFT outer foveal thickness, CT choroidal thickness